The Evolut Low Risk Trial

Michael J. Reardon and C. Michael Gibson discuss the 5-year outcomes of TAVR or SAVR in low-risk patients with AS.

Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.

William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.

Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.

Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.

How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.

In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.

Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.

Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.

Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.